Mark S Carey (Mark Carey)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 8

Top Topics

Peritoneal Dialysis

Top Venues

Current oncology (Toronto, Ont.)

Cancer research

British journal of cancer

NPJ precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Laura Hopkins, Mark S Carey, Linda Brown, Sabryna McCrea, Mark Milne, Dawne Tokaryk, Shi Wu Wen
The Development and Testing of a Patient Decision Aid for Individuals with Homologous Recombinant Proficient Ovarian Cancer Who Are Considering Niraparib Maintenance Therapy. Current oncology (Toronto, Ont.) 31 (3) (2024)
Laura Hopkins, Mark S Carey, Linda Brown, Sabryna McCrea, Mark Milne, Dawne Tokaryk, Shi Wu Wen
The Development and Testing of a Patient Decision Aid for Individuals with Homologous Recombinant Proficient Ovarian Cancer Who Are Considering Niraparib Maintenance Therapy. Current oncology (Toronto, Ont.) 31 (3) (2024)
Laura Hopkins, Mark S Carey, Linda Brown, Sabryna McCrea, Mark Milne, Dawne Tokaryk, Shi Wu Wen
The Development and Testing of a Patient Decision Aid for Individuals with Homologous Recombinant Proficient Ovarian Cancer Who Are Considering Niraparib Maintenance Therapy. Current oncology (Toronto, Ont.) 31 (3) (2024)
Laura Hopkins, Mark S Carey, Linda Brown, Sabryna McCrea, Mark Milne, Dawne Tokaryk, Shi Wu Wen
The Development and Testing of a Patient Decision Aid for Individuals with Homologous Recombinant Proficient Ovarian Cancer Who Are Considering Niraparib Maintenance Therapy. Current oncology (Toronto, Ont.) 31 (3) (2024)
Mattia Cremona, Cassandra J Vandenberg, Angela M Farrelly, Stephen F Madden, Clare Morgan, Roshni Kalachand, Jessica N McAlpine, Sinead Toomey, David G Huntsman, Liam Grogan, Oscar Breathnach, Patrick Morris, Mark S Carey, Clare L Scott, Bryan T Hennessy
BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors. British journal of cancer 127 (3) (2022)
Marta Llaurado Fernandez, E Marielle Hijmans, Annemiek M C Gennissen, Nelson K Y Wong, Shang Li, G Bea A Wisman, Aleksandra Hamilton, Joshua Hoenisch, Amy Dawson, Cheng-Han Lee, Madison Bittner, Hannah Kim, Gabriel E DiMattia, Christianne A R Lok, Cor Lieftink, Roderick L Beijersbergen, Steven de Jong, Mark S Carey, René Bernards, Katrien Berns
NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition. Molecular cancer therapeutics 21 (12) (2022)
Dane Cheasley, Marta Llaurado Fernandez, Martin Koebel, Hannah Kim, Amy Dawson, Joshua Hoenisch, Madison Bittner, Derek S Chiu, Aline Talhouk, C Blake Gilks, Madawa W Jayawardana, Kathleen I Pishas, Anne-Marie Mes-Masson, Diane Provencher, Abhimanyu Nigam, Neville F Hacker, Kylie L Gorringe, Ian G Campbell, Mark S Carey
Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression. NPJ precision oncology 6 (1) (2022)
Raunak Shrestha, Marta Llaurado Fernandez, Amy Dawson, Joshua Hoenisch, Stanislav Volik, Yen-Yi Lin, Shawn Anderson, Hannah Kim, Anne M Haegert, Shane Colborne, Nelson K Y Wong, Brian McConeghy, Robert H Bell, Sonal Brahmbhatt, Cheng-Han Lee, Gabriel E DiMattia, Stephane Le Bihan, Gregg B Morin, Colin C Collins, Mark S Carey
Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability. Cancer research 81 (7) (2021)